U.S.-Israel Binational Science Foundation grant for pediatric brain tumor research awarded to co-principal investigators Castro and Friedman-Morbinski

Michigan Medicine and Tel Aviv University investigators will study strategies to improve CAR T-cell therapy for diffuse hemispheric gliomas.

Headshot of Dr. Maria Castro

ANN ARBOR, Mich. — October 30, 2026 — Maria G. Castro, Ph.D., R. C. Schneider Collegiate Professor of Neurosurgery and Professor of Cell & Developmental Biology at the University of Michigan Medical School, has received a competitive research award from the U.S.-Israel Binational Science Foundation.

Castro will conduct the project in collaboration with co-principal investigator Dinorah Friedmann-Morvinski, Ph.D., Associate Professor in the Department of Biochemistry and Molecular Biology at the George S. Wise Faculty of Life Sciences and the Sagol School of Neuroscience at Tel Aviv University.

Their project, “Boosting the CAR T efficacy by modulating the microenvironment in diffuse hemispheric gliomas,” will investigate strategies for improving chimeric antigen receptor (CAR) T-cell therapy for aggressive pediatric brain tumors. The project is supported under Binational Science Foundation application 2021070.

Diffuse hemispheric gliomas are aggressive pediatric central nervous system tumors that remain difficult to treat. Although CAR T-cell therapy has transformed care for some blood cancers, its effectiveness against solid tumors remains limited by challenges that include an immunosuppressive tumor microenvironment, tumor heterogeneity and the scarcity of tumor antigens that can be targeted safely and consistently.

Castro and Friedmann-Morvinski hypothesize that localized immunosuppression contributes to T-cell exhaustion and tumor regrowth. Their study will test whether combining CAR T-cell therapy with treatments that reprogram the tumor microenvironment can improve therapeutic outcomes.

Using immunocompetent genetically engineered mouse models designed to closely reflect the genetic lesions encountered in human diffuse hemispheric gliomas, the research team will evaluate small-molecule inhibitors and CAR T cells mediated-immunotherapies. To this effect, the investigators will engineer dual CAR T cells that target both conventional and nonconventional tumor-associated antigens.

The team will characterize the tumor microenvironment, with a particular focus on gliomas carrying the H3.3-G34 mutation. “These findings will guide the development of precision-medicine based treatments intended to overcome immunosuppression, including approaches that target the STING signaling pathway.” – Castro said.

The researchers aim to establish an integrated treatment strategy that combines CAR T-cell therapy with tumor-microenvironment modulation. The work could deepen understanding of how the microenvironment affects tumor growth and immune evasion and help inform mutation-specific combination immunotherapies for children with these devastating brain cancers.

“CAR T cells have not yet delivered on their promise in the brain. Our hypothesis is that the immunosuppressive microenvironment exhausts T cells and allows tumors to regrow. By combining CAR T-cell therapy with strategies that reprogram that microenvironment, including targeting the STING pathway, we hope to develop effective treatments that offer children and their family’s new options.” Said Fridman-Morbinsky. We are very grateful to the Binational Science Foundation for supporting this collaboration between Michigan and Tel Aviv University.

The U.S.-Israel Binational Science Foundation supports collaborative research involving scientists from the United States and Israel.


More Articles About:

Brain Tumor Pediatric Cancer

In This Story

portrait of Maria Castro

Maria Castro, PhD

Professor

Featured News & Stories

Smiling portrait of Jack Fineske. He has short brown hair and is wearing a red sweater.
Philanthropy News

Catching Up With Jack

Nonprofit organization Catching Up With Jack fuels leading-edge pediatric brain cancer research while honoring a journey of courage and faith.
brain scan on computer
Health Lab

FDA clears new DMG treatment: What it means for a deadly pediatric brain tumor

Diffuse midline gliomas are aggressive tumors that begin in the brain or spinal cord. It is universally fatal, and patients typically live for nine to 15 months after diagnosis. The FDA has approved ONC201 (dordaviprone) to treat recurrent H3K27M-mutant diffuse glioma. It's the first-ever FDA-approved treatment for this disease.
woman in hospital on left in ICU and the other right side woman standing in jean jacket and black clothes smiling
Health Lab

Brain tumor and car crash survivor aspires to be example for others living with disabilities

A car accident at age 20 left Sahar Mashhour in the intensive care unit for three months. Almost six years later, Mashhour is still pursuing her passions proving that her disability doesn’t limit her ability, but instead helps her see life through a different lens.
boy dressed as spiderman next to woman red hair smiling and man sitting on floor in playroom
Health Lab

Talent show brings joy to kids at children’s hospital 

A weekly talent show at University of Michigan Health C.S. Mott Children's Hospital helps pediatric cancer patients and families find support, healing and happiness through music, magic, and creative expression.
baby with sparkling head ban smiling in house
Health Lab

U-M alumni return from Central Asia to seek treatment for their child at Mott

After a leukemia diagnosis overseas, a young girl returned to Michigan for expert pediatric cancer care at C.S. Mott Children’s Hospital.
Headshot of Abel, a smiling toddler wearing a headband with two gold pompoms.
Philanthropy News

Block Out Cancer: From a crisis abroad to answers at Mott

Your gift to Block Out Cancer helps children like Abel overcome childhood cancer. Donations fill critical gaps for lifesaving pediatric cancer research and care at C.S. Mott Children's Hospital.